Non-Hodgkin’s lymphoma drug company gets $15M venture backing
A specialty pharmaceutical company has secured $15 million in venture debt backing for its topical gel drug to treat the early stages of mycosis fungoides, a type of non-Hodgkin’s lymphoma. The investment will go toward operational expenses and commercializing the drug, for which a new drug application (NDA) has been submitted to the U.S. Food […]